Drug intelligence / Profile preview

arbekacin sulfate + levofloxacin + minocycline hydrochloride

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Intravenous, Intramuscular

Overview

A combination antibiotic therapy consisting of arbekacin sulfate (an aminoglycoside), levofloxacin (a fluoroquinolone), and minocycline hydrochloride (a tetracycline). This combination has been used to treat methicillin-resistant Staphylococcus aureus (MRSA) infections, particularly in cases involving biofilm or persistent infections. Each component works through different mechanisms to inhibit bacterial growth and survival, providing a multi-targeted approach to combat resistant bacterial infections.

Targets

Topo IV (Bacterial Topoisomerase IV)Bacterial RibosomeDNA gyrase

Beyond the preview

Go deeper on arbekacin sulfate + levofloxacin + minocycline hydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on arbekacin sulfate + levofloxacin + minocycline hydrochloride.

Explore the full profile